secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001193125-23-275384
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma Q1 net loss $6M; 19 OPMD subjects enrolled; BB-301 dosing expected Dec/Jan
--------------------------------------------------------------------------------

- Net loss of $6.0M ($2.76 per share) vs $5.1M ($7.98 per share) in Q1 FY2023; higher share count reduced per-share loss.
- Cash and equivalents $25.9M at Sep 30, 2023, up from $2.5M at Jun 30, 2023, extending runway.
- R&D expense $4.4M (up 66% YoY) driven by BB-301 clinical development; G&A $1.6M (down 19% YoY).
- 19 subjects enrolled in OPMD Natural History Study as of Oct 2023; first BB-301 dose planned Dec 2023 or Jan 2024.
- FDA IND clearance received; Canadian REB submission completed; interim safety/efficacy data expected within 12 months of first dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523275384/0001193125-23-275384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523275384/d85932d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-275384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer